Tagged with GI

Belgium Speaking exclusively to PharmaBoardroom, Pedro Facon outlines the scope and aims of the new medicines roadmap that NIHDI has recently presented to the Belgian Ministry of Health following extensive stakeholder discussions in 2022. In a wide-ranging and in-depth conversation, Facon describes his hopes for tackling the growing number and length…

Belgium An Van Gerven took the reins of Pfizer’s BeLux affiliate just 9 months ago after a diverse range of roles at the company over the course of 12 years. She highlights some of her key priorities and explains Belgium’s strategic importance for Pfizer – a country where it has its…

Belgium PDC*line Pharma’s Eric Halioula explains why he decided to establish a biotech in Belgium, outlines the progress that his immuno-oncology focused firm has made in clinical trials since our last conversation in 2020, and his hopes for establishing new alliances with manufacturers and Big Pharma players moving forward.   Our…

Belgium Once primarily associated with dispensing medications alone, many pharmacies have now evolved into dynamic healthcare hubs, offering a diverse range of services that extend far beyond traditional prescription filling. Similarly, pharmacists have emerged as crucial members of the healthcare team, playing integral roles in patient care, medication management, and promoting…

Belgium The concepts of patient-centricity and patient-centred healthcare systems have been much discussed in recent years but, in the opinion of Stefan Gijssels, there is still a long road to travel to fully realise them. Gijssels – a 20-year pharma industry veteran whose personal experience of cancer led to him joining…

UAE 16-year Gilead veteran, Vítor Papão, recently left Europe to take on a new role within the company as general manager of the vast Middle East & Russia cluster. He discusses the particularities of the region, and the partnerships and initiatives Gilead is actively pursuing with local stakeholders.   We have…

Belgium Pierre Boyer, GM at Servier BeLux for the past six years, outlines the unique characteristics and challenges of the Belgian market and shares the company’s 2030 strategy, its unique approach to oncology with a focus on hard-to-treat cancers, as well as its focus on patient centricity   In oncology, we…

Belgium Gedeon Richter Benelux’s Isabelle de Walsche gives an update on the affiliate’s progress towards becoming a reference player in women’s health, looks back on some of her achievements over 11 years in position, and highlights some of the key issues on her agenda as pharma.be’s SME subgroup chair.   The…

Belgium Luc Van Gorp is president of the Christian Mutuality, Belgium’s largest health insurance fund. In a wide-ranging recent conversation with PharmaBoardroom, Van Gorp expanded on some of the key themes in his 2021 book ‘Human Scale: A Plea for Imperfection’ (‘Mensenmaat: Een Pleidooi Voor Imperfectie’ in Dutch), including why innovation…

Belgium Xavier De Cuyper of the Federal Agency for Medicines & Health Products (FAMHP), Belgium’s drug regulator, explains the FAMHP’s pandemic response and lessons learned, how the Agency is keeping on top of the rapidly evolving technologies being brought forward today, and the significance of a new early access programme for…

Belgium Gábor Sztaniszláv talks through the global relevance of Belux to Amgen’s operations, some of the challenging market access conditions at play – especially for orphan drugs -, and how the company’s biosimilar portfolio has the potential to contribute to significant savings for the healthcare system.   Improving the evaluation process…

Belgium Marc Gryseels of BACHI, Belgium’s over-the-counter (OTC) medicines association, highlights the organisation’s mission and vision, the key trends at play within the Belgian consumer healthcare market, and his industry’s significant role within Europe.   I believe it is high time for Belgium to have price freedom in the OTC medicine…